Invesco Ltd. Purchases 22,562 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Invesco Ltd. increased its stake in Supernus Pharmaceuticals by 4.4%, owning approximately 0.95% of the company valued at $17.38 million after acquiring additional shares.
• Supernus Pharmaceuticals has received recent upgrades from analysts, with Cantor Fitzgerald raising the target price from $42.00 to $46.00 and Wall Street Zen upgrading its rating from "hold" to "buy."
• There has been significant insider selling, with directors collectively selling over 152,826 shares valued at approximately $6.42 million in the last 90 days.

Invesco Ltd. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 530,631 shares of the specialty pharmaceutical company's stock after purchasing an additional 22,562 shares during the quarter. Invesco Ltd. owned 0.95% of Supernus Pharmaceuticals worth $17,378,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vident Advisory LLC grew its holdings in shares of Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock valued at $520,000 after purchasing an additional 309 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Supernus Pharmaceuticals by 2.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock worth $480,000 after buying an additional 350 shares during the period. Bank of Montreal Can boosted its stake in Supernus Pharmaceuticals by 6.6% during the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after buying an additional 473 shares during the period. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth $25,000. Finally, PNC Financial Services Group Inc. boosted its stake in Supernus Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock worth $527,000 after buying an additional 726 shares during the period.

Supernus Pharmaceuticals Trading Up 1.7%

Shares of SUPN traded up $0.75 during trading hours on Wednesday, reaching $45.07. 680,753 shares of the company traded hands, compared to its average volume of 1,066,379. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of 39.19 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The stock's fifty day moving average price is $36.13 and its 200 day moving average price is $33.85.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company's stock, valued at $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 179,606 shares of company stock valued at $7,617,005 over the last three months. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.